Vea MedIQ en Español
Os autores concluíram que o uso de ezetimiba, em pacientes já recebendo sinvastatina 40 mg, não se associa ao aumento do...
IMPROVE-IT avalia possível risco aumentado de câncer em pacientes em uso de ezetimiba
Escrito por: MDHealth em 29 de março de 2021
2 min de leitura
Referências
Giugliano RP, Gencer B, Wiviott SD, et al. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT
Sabatine MS, Wiviott SD, Im K, et al. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol 2018;3: 823–828.
Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol 2019;73:e285–e350.
Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11(11):CD012502.
